GlassScriptPhysician profile
Kitty Victoria
NPI 1871917633
$2,591.86
in general payments reported to CMS, 2019-2025
30 companies · $291 in 2025
The $291 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.90 · 2020: $91.67 · 2021: $287 · 2022: $744 · 2023: $1,057 · 2024: $111 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,199 · Education: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,199.12 |
| Education | $259.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $519.31 | 2021-2023 | Xtandi |
| Tempus Ai, INC | $301.75 | 2024-2025 | Xt Cdx |
| E.R. Squibb & Sons, L.L.C. | $219.79 | 2021-2023 | Opdualag, Opdivo, Reblozyl |
| Amgen INC. | $205.17 | 2020-2025 | Actimmune, Kyprolis, Blincyto |
| Pfizer INC. | $181.82 | 2019-2023 | |
| Janssen Biotech, INC. | $163.34 | 2021-2023 | Rybrevant, Erleada, Darzalex |
| Astrazeneca Pharmaceuticals LP | $123.21 | 2021-2023 | Enhertu, Imfinzi |
| Merck Sharp & Dohme LLC | $95.30 | 2021-2023 | Keytruda, Lenvima |
| Aveo Pharmaceuticals, INC. | $84.50 | 2022 | |
| Genentech USA, INC. | $65.95 | 2022-2023 | Rozlytrek, Gavreto, Alecensa |
| Exelixis INC. | $64.71 | 2021-2023 | Cabometyx |
| Acrotech Biopharma INC. | $54.65 | 2021-2022 | |
| Myovant Sciences INC. | $54.52 | 2021-2022 | |
| Sobi, INC | $53.97 | 2022-2023 | |
| Genzyme Corporation | $53.27 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $46.78 | 2022-2023 | Libtayo |
| Eisai INC. | $41.87 | 2022-2023 | |
| Array Biopharma INC | $35.84 | 2023 | Mektovi, Braftovi, Paxlovid |
| Novartis Pharmaceuticals Corporation | $28.69 | 2023 | |
| Lilly USA, LLC | $25.85 | 2023 | Retevmo, Jaypirca, Verzenio |
| Incyte Corporation | $25.13 | 2023 | Monjuvi, Pemazyre |
| Servier Pharmaceuticals LLC | $21.19 | 2023 | |
| Sun Pharmaceutical Industries INC. | $19.50 | 2022 | |
| Sumitomo Pharma America, INC. | $18.79 | 2023 | Orgovyx |
| Karyopharm Therapeutics INC. | $18.00 | 2023 | Xpovio |
| Clovis Oncology, INC. | $16.16 | 2022 | |
| Blueprint Medicines Corporation | $14.93 | 2021 | |
| Alexion Pharmaceuticals, INC. | $13.06 | 2023 | Ultomiris |
| Foundation Medicine, INC. | $12.89 | 2023 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kitty Victoria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.